| Recently Developed Therapeutic Agents for B-cell Non-Hodgkin Lymphoma |
|
Byeong-Bae Park |
|
Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea |
| 최근 개발된 B-세포 림프종의 치료 약제 |
|
박병배 |
|
한양대학교 의과대학 내과학교실 혈액종양내과 |
Correspondence:
Byeong-Bae Park, Tel: +82-2-2290-8335, Fax: +82-2-2298-9183, Email: bbpark@hanyang.ac.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
While most B-cell lymphomas are cured by chemotherapy, in recent years research interest has focused on the development of monoclonal antibodies and small molecules targeting membrane proteins, components of signaling pathways or tumor micro-environment, which are factors essential for the development and progression of lymphomas. Some of these new drugs have shown substantial clinical activity in phase I and small phase II studies in patients with relapsed and refractory disease, with response rates of up to 50-60% in some cases. These results give hope for patients who have standard treatment failure; however, their incorporation into commonly used regimens also represents a significant challenge for the future. |
| Key Words:
Treatment; B-cell lymphoma; Lymphoma |
| 주제어:
치료; B세포 림프종; 림프종 |
|
PDF Links
Full text via DOI
Download Citation
